References
1 Navari RM, Aapro M. Antiemetic prophylaxis
for chemotherapy-induced nausea and vomiting.
N Engl J Med 2016;374(14):1356–67.
2 Hesketh P et al. Antiemetics: American Society
of Clinical Oncology Clinical Practice Guideline
Update. J Clin Oncol 2017;35(28):3240–61.
3 Hesketh PJ. Prevention and treatment of
chemotherapy-induced nausea and vomiting
in adults. In: UpToDate, UpToDate, Waltham,
MA, 2019. www.uptodate.com/home/index.html
(accessed July 2019).
4 Roila F et al. Guideline update for MASCC and
ESMO in the prevention of chemotherapy and
radiotherapy-induced nausea and vomiting:
results of the Perugia consensus conference.
Ann Oncol 2010;S5:v232-v243.
5 Einhorn LH et al. 2016 updated MASCC/ESMO
consensus recommendations: prevention of
nausea and vomiting following multiple-day
chemotherapy, high-dose chemotherapy, and
breakthrough nausea and vomiting. Support
Care Cancer 2017;25(1):303–8.
6 American Society of Clinical Oncology.
Antiemetics focused update. www.asco.org/
(accessed May 2019).
7 National Comprehensive Cancer Network
(NCCN) Clinical Practice Guidelines in Oncology
(NCCN Guidelines ® ): Antiemesis. Version 1.2019.
www.nccn.org/professionals/physician_gls/pdf/
antiemesis.pdf (accessed July 2019).
8 European Society for Medical Oncology. www.
esmo.org/Guidelines/Supportive-and-Palliative-
Care / (accessed July 2019).
9 Multinational Association of Supportive Care
in Cancer. MASCC/ESMO Antiemetic Guidelines.
www.mascc.org/antiemetic-guidelines /
(accessed July 2019).
10 Kaiser R et al. Patient-tailored antiemetic
treatment with 5-hydroxytryptamine
type 3 receptor antagonists according to
cytochrome P-450 2D6 genotypes. J Clin Oncol
2002;20(12):2805–11.
11 Jordan K et al. A meta-analysis comparing
the efficacy of four 5-HT3-receptor antagonists
for acute chemotherapy-induced emesis.
Support Care Cancer 2007;15:1023–33.
12 Navari RM et al. Comparative clinical trial of
granisetron and ondansetron in the prophylaxis
of cisplatin-induced emesis. J Clin Oncol
1995;13:1242–8.
13 Italian Group for Antiemetic Research.
Ondansetron versus granisetron, both combined
with dexamethasone, in the prevention
of cisplatin-induced emesis. Ann Oncol
1995;6:805–10.
66 | 2019 | hospitalpharmacyeurope.com
14 Navari R et al. Comparative clinical trial of
granisetron and ondansetron in the prophylaxis
of cisplatin-induced emesis. The Granisetron
Study Group. J Clin Oncol 1995;13(5):1242–8.
15 Marty M et al. Is Navoban (tropisetron) as
effective as Zofran (ondansetron) in cisplatin-
induced emesis? The French Navoban Study
Group. Anticancer Drugs 1995;6 Suppl 1:15–21.
16 Gandara DR et al. Consensus proposal
for 5HT3 antagonists in the prevention of
acute emesis related to highly emetogenic
chemotherapy. Dose, schedule, and route
of administration. Support Care Cancer
1998;6(3):237–43.
17 Patel P et al. Safety of clinical practice
guideline-recommended antiemetic agents for
the prevention of acute chemotherapy-induced
nausea and vomiting in pediatric patients: a
systematic review and meta-analysis. Expert
Opin Drug Saf 2019;18(2):97–110.
18 Nadaraja S et al. Palonosetron for the
prevention of nausea and vomiting in children
with acute lymphoblastic leukemia treated with
high dose methotrexate. Pediatr Blood Cancer
2012;59(5):870–3.
19 Aloxi. Summary of Product Characteristics.
www.medicines.org.uk/emc/ (accessed June
2018).
20 Aapro MS et al. A phase III, double-blind,
randomized trial of palonosetron compared
with ondansetron in preventing chemotherapy-
induced nausea and vomiting following
highly emetogenic chemotherapy. Ann Oncol
2006;17(9):1441–9.
21 Saito M et al. Palonosetron plus
dexamethasone versus granisetron plus
dexamethasone for prevention of nausea and
vomiting during chemotherapy: a double-blind,
double-dummy, randomised, comparative phase
III trial. Lancet Oncol 2009;10:115–24.
22 Morganroth J et al. Effect of single doses
of IV palonosetron, up to 2.25 mg, on the QTc
interval duration: a double-blind, randomized,
parallel group study in healthy volunteers.
Support Care Cancer 2016;24(2):621–7.
23 Bountra C et al. Anti-emetic profile of a non-
peptide neurokinin NK1 receptor antagonist,
CP-99,994, in ferrets. Eur J Pharmacol
1993;249(1):R3–4.
24 Warr DG et al. The oral NK(1) antagonist
aprepitant for the prevention of acute and
delayed chemotherapy-induced nausea and
vomiting: Pooled data from 2 randomised,
double-blind, placebo controlled trials. Eur
J Cancer 2005;41(9):1278–85.
25 Warr DG et al. Efficacy and tolerability of